Teplizumab for newly diagnosed type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 25 years old
- Have been diagnosed with stage 3 type 1 diabetes within the last 8 weeks
- Have at least one diabetes-related antibody in a blood test
- Have a C-peptide level of 0.2 nmol/L or higher
- Be able to start the study drug within 56 days of diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.